| Aurobindo Pharma announced that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Unit IV, a Formulation
manufacturing facility, of APL Healthcare, a wholly owned subsidiary of the Company, situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from 13 September to 19 September 2023.
The Unit has now received Establishment Inspection Report classifying the facility as "Voluntary Action Indicated" (VAI). |